<?xml version='1.0' encoding='utf-8'?>
<document id="9375595"><sentence text="Effect of sertraline on plasma nortriptyline levels in depressed elderly."><entity charOffset="10-20" id="DDI-PubMed.9375595.s1.e0" text="sertraline" /><entity charOffset="31-44" id="DDI-PubMed.9375595.s1.e1" text="nortriptyline" /><pair ddi="false" e1="DDI-PubMed.9375595.s1.e0" e2="DDI-PubMed.9375595.s1.e0" /><pair ddi="false" e1="DDI-PubMed.9375595.s1.e0" e2="DDI-PubMed.9375595.s1.e1" /></sentence><sentence text="Several serotonin selective reuptake inhibitors have been reported to be inhibitors of the cytochrome P450 2D6 (CYP2D6)"><entity charOffset="8-17" id="DDI-PubMed.9375595.s2.e0" text="serotonin" /></sentence><sentence text=" Thus, they may increase the plasma level of secondary amine tricyclic antidepressants, which are predominantly metabolized through this enzyme" /><sentence text=" Except for a few case reports, no clinical data document the degree of this drug-drug interaction in elderly depressed patients" /><sentence text="" /><sentence text="We systematically examined this interaction by determining the change in plasma nortriptyline levels in 14 elderly depressed patients in whom sertraline was added to nortriptyline"><entity charOffset="142-152" id="DDI-PubMed.9375595.s6.e0" text="sertraline" /><entity charOffset="166-179" id="DDI-PubMed.9375595.s6.e1" text="nortriptyline" /><pair ddi="false" e1="DDI-PubMed.9375595.s6.e0" e2="DDI-PubMed.9375595.s6.e0" /><pair ddi="false" e1="DDI-PubMed.9375595.s6.e0" e2="DDI-PubMed.9375595.s6.e1" /></sentence><sentence text="" /><sentence text="After addition of 50 mg/day of sertraline, the median increase in plasma nortriptyline level over baseline was 2% (range, -26% to 117%; p = "><entity charOffset="31-41" id="DDI-PubMed.9375595.s8.e0" text="sertraline" /></sentence><sentence text="30)" /><sentence text=" In 2 patients (14%), there was an increase of 50% or more" /><sentence text=" For patients taking higher sertraline doses (N = 7; 100 or 150 mg/day), the median increase in plasma nortriptyline level over baseline was 40% (range, -12% to 239%; p = "><entity charOffset="46-47" id="DDI-PubMed.9375595.s11.e0" text="N" /></sentence><sentence text="08)" /><sentence text="" /><sentence text="Overall, a modest effect of sertraline was observed on nortriptyline metabolism in these elderly depressed patients"><entity charOffset="28-38" id="DDI-PubMed.9375595.s14.e0" text="sertraline" /><entity charOffset="55-68" id="DDI-PubMed.9375595.s14.e1" text="nortriptyline" /><pair ddi="false" e1="DDI-PubMed.9375595.s14.e0" e2="DDI-PubMed.9375595.s14.e0" /><pair ddi="false" e1="DDI-PubMed.9375595.s14.e0" e2="DDI-PubMed.9375595.s14.e1" /></sentence><sentence text=" This is consistent with prior reports of a weak inhibition of CYP2D6 by sertraline in vitro and in young healthy volunteers"><entity charOffset="73-83" id="DDI-PubMed.9375595.s15.e0" text="sertraline" /></sentence><sentence text=" However, some patients showed a change in plasma nortriptyline level that would be considered clinically significant"><entity charOffset="50-63" id="DDI-PubMed.9375595.s16.e0" text="nortriptyline" /></sentence><sentence text=" Thus, careful monitoring of plasma nortriptyline levels is recommended in all patients treated with a combination of nortriptyline and sertraline"><entity charOffset="36-49" id="DDI-PubMed.9375595.s17.e0" text="nortriptyline" /><entity charOffset="118-131" id="DDI-PubMed.9375595.s17.e1" text="nortriptyline" /><entity charOffset="136-146" id="DDI-PubMed.9375595.s17.e2" text="sertraline" /><pair ddi="false" e1="DDI-PubMed.9375595.s17.e0" e2="DDI-PubMed.9375595.s17.e0" /><pair ddi="false" e1="DDI-PubMed.9375595.s17.e0" e2="DDI-PubMed.9375595.s17.e1" /><pair ddi="false" e1="DDI-PubMed.9375595.s17.e0" e2="DDI-PubMed.9375595.s17.e2" /><pair ddi="false" e1="DDI-PubMed.9375595.s17.e1" e2="DDI-PubMed.9375595.s17.e1" /><pair ddi="false" e1="DDI-PubMed.9375595.s17.e1" e2="DDI-PubMed.9375595.s17.e2" /></sentence><sentence text="" /></document>